300 related articles for article (PubMed ID: 19456105)
1. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
Bogen SL; Pan W; Ruan S; Nair LG; Arasappan A; Bennett F; Chen KX; Jao E; Venkatraman S; Vibulbhan B; Liu R; Cheng KC; Guo Z; Tong X; Saksena AK; Girijavallabhan V; Njoroge FG
J Med Chem; 2009 Jun; 52(12):3679-88. PubMed ID: 19456105
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
Bogen SL; Arasappan A; Velazquez F; Blackman M; Huelgas R; Pan W; Siegel E; Nair LG; Venkatraman S; Guo Z; Doll R; Shih NY; Njoroge FG
Bioorg Med Chem; 2010 Mar; 18(5):1854-65. PubMed ID: 20149666
[TBL] [Abstract][Full Text] [Related]
3. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
4. Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication.
Bogen SL; Arasappan A; Bennett F; Chen K; Jao E; Liu YT; Lovey RG; Venkatraman S; Pan W; Parekh T; Pike RE; Ruan S; Liu R; Baroudy B; Agrawal S; Chase R; Ingravallo P; Pichardo J; Prongay A; Brisson JM; Hsieh TY; Cheng KC; Kemp SJ; Levy OE; Lim-Wilby M; Tamura SY; Saksena AK; Girijavallabhan V; Njoroge FG
J Med Chem; 2006 May; 49(9):2750-7. PubMed ID: 16640336
[TBL] [Abstract][Full Text] [Related]
5. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
Arasappan A; Padilla AI; Jao E; Bennett F; Bogen SL; Chen KX; Pike RE; Sannigrahi M; Soares J; Venkatraman S; Vibulbhan B; Saksena AK; Girijavallabhan V; Tong X; Cheng KC; Njoroge FG
J Med Chem; 2009 May; 52(9):2806-17. PubMed ID: 19371095
[TBL] [Abstract][Full Text] [Related]
6. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
[TBL] [Abstract][Full Text] [Related]
7. Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.
Bogen SL; Ruan S; Liu R; Agrawal S; Pichardo J; Prongay A; Baroudy B; Saksena AK; Girijavallabhan V; Njoroge FG
Bioorg Med Chem Lett; 2006 Mar; 16(6):1621-7. PubMed ID: 16387495
[TBL] [Abstract][Full Text] [Related]
8. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.
Mederacke I; Wedemeyer H; Manns MP
Curr Opin Investig Drugs; 2009 Feb; 10(2):181-9. PubMed ID: 19197796
[TBL] [Abstract][Full Text] [Related]
9. Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
Chen KX; Nair L; Vibulbhan B; Yang W; Arasappan A; Bogen SL; Venkatraman S; Bennett F; Pan W; Blackman ML; Padilla AI; Prongay A; Cheng KC; Tong X; Shih NY; Njoroge FG
J Med Chem; 2009 Mar; 52(5):1370-9. PubMed ID: 19196021
[TBL] [Abstract][Full Text] [Related]
10. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
Venkatraman S; Velazquez F; Wu W; Blackman M; Chen KX; Bogen S; Nair L; Tong X; Chase R; Hart A; Agrawal S; Pichardo J; Prongay A; Cheng KC; Girijavallabhan V; Piwinski J; Shih NY; Njoroge FG
J Med Chem; 2009 Jan; 52(2):336-46. PubMed ID: 19102654
[TBL] [Abstract][Full Text] [Related]
11. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
12. Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
Venkatraman S; Velazquez F; Wu W; Blackman M; Madison V; Njoroge FG
Bioorg Med Chem Lett; 2010 Apr; 20(7):2151-5. PubMed ID: 20226659
[TBL] [Abstract][Full Text] [Related]
13. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
Venkatraman S; Blackman M; Wu W; Nair L; Arasappan A; Padilla A; Bogen S; Bennett F; Chen K; Pichardo J; Tong X; Prongay A; Cheng KC; Girijavallabhan V; George Njoroge F
Bioorg Med Chem; 2009 Jul; 17(13):4486-95. PubMed ID: 19481946
[TBL] [Abstract][Full Text] [Related]
15. Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
Velázquez F; Sannigrahi M; Bennett F; Lovey RG; Arasappan A; Bogen S; Nair L; Venkatraman S; Blackman M; Hendrata S; Huang Y; Huelgas R; Pinto P; Cheng KC; Tong X; McPhail AT; Njoroge FG
J Med Chem; 2010 Apr; 53(8):3075-85. PubMed ID: 20302300
[TBL] [Abstract][Full Text] [Related]
16. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
Nair LG; Sannigrahi M; Bogen S; Pinto P; Chen KX; Prongay A; Tong X; Cheng KC; Girijavallabhan V; George Njoroge F
Bioorg Med Chem Lett; 2010 Jan; 20(2):567-70. PubMed ID: 20004570
[TBL] [Abstract][Full Text] [Related]
17. Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue.
Chen KX; Vibulbhan B; Yang W; Cheng KC; Liu R; Pichardo J; Butkiewicz N; Njoroge FG
Bioorg Med Chem; 2008 Feb; 16(4):1874-83. PubMed ID: 18032054
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
Vendeville S; Nilsson M; de Kock H; Lin TI; Antonov D; Classon B; Ayesa S; Ivanov V; Johansson PO; Kahnberg P; Eneroth A; Wikstrom K; Vrang L; Edlund M; Lindström S; Van de Vreken W; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Van Dooren M; Kindermans N; Surleraux D; Wigerinck P; Rosenquist A; Samuelsson B; Simmen K; Raboisson P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6189-93. PubMed ID: 18954982
[TBL] [Abstract][Full Text] [Related]
19. Potent aza-peptide derived inhibitors of HCV NS3 protease.
Venkatraman S; Wu W; Shih NY; George Njoroge F
Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
[TBL] [Abstract][Full Text] [Related]
20. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
